This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor adherence
Timeframe: During pregnancy (up to 40 weeks) through 6 months post-delivery
Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor dosing
Timeframe: During pregnancy (up to 40 weeks) through 6 months post-delivery
Safety of mTOR inhibitor in Pregnancy -- side effects
Timeframe: During pregnancy (up to 40 weeks) through 6 months post-delivery
Maternal-Fetal Complications in TSC
Timeframe: During pregnancy (up to 40 weeks)
Maternal Post-Partum Behavioral Health
Timeframe: Post-partum up to 6 months
Maternal Post-Partum Mental Health
Timeframe: Post-partum up to 6 months
Optimum Time of Fetal Imaging for TSC
Timeframe: Birth through 5 years of Age